Janney Montgomery Scott LLC Raises Stock Holdings in IQVIA Holdings Inc. (NYSE:IQV)

Janney Montgomery Scott LLC grew its stake in shares of IQVIA Holdings Inc. (NYSE:IQV) by 3.3% during the fourth quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The institutional investor owned 36,512 shares of the medical research company’s stock after buying an additional 1,172 shares during the period. Janney Montgomery Scott LLC’s holdings in IQVIA were worth $7,175,000 at the end of the most recent reporting period.

A number of other hedge funds also recently made changes to their positions in the stock. AQR Capital Management LLC boosted its stake in shares of IQVIA by 173.8% in the second quarter. AQR Capital Management LLC now owns 90,689 shares of the medical research company’s stock worth $19,175,000 after acquiring an additional 57,568 shares during the period. Magnolia Capital Advisors LLC boosted its stake in IQVIA by 7.9% in the 2nd quarter. Magnolia Capital Advisors LLC now owns 3,041 shares of the medical research company’s stock worth $643,000 after purchasing an additional 223 shares during the period. NewEdge Advisors LLC grew its holdings in IQVIA by 4.8% during the 2nd quarter. NewEdge Advisors LLC now owns 20,119 shares of the medical research company’s stock valued at $4,254,000 after buying an additional 918 shares in the last quarter. Northwestern Mutual Wealth Management Co. lifted its holdings in shares of IQVIA by 8.4% in the second quarter. Northwestern Mutual Wealth Management Co. now owns 10,252 shares of the medical research company’s stock worth $2,168,000 after buying an additional 795 shares in the last quarter. Finally, Quarry LP boosted its position in shares of IQVIA by 272.9% during the second quarter. Quarry LP now owns 619 shares of the medical research company’s stock worth $131,000 after acquiring an additional 453 shares during the last quarter. 89.62% of the stock is currently owned by institutional investors.

Wall Street Analyst Weigh In

IQV has been the topic of several research reports. JPMorgan Chase & Co. reduced their target price on IQVIA from $279.00 to $240.00 and set an “overweight” rating on the stock in a report on Tuesday, November 5th. William Blair reaffirmed an “outperform” rating on shares of IQVIA in a report on Wednesday, December 11th. Evercore ISI cut their target price on shares of IQVIA from $270.00 to $265.00 and set an “outperform” rating for the company in a report on Tuesday, October 8th. BTIG Research decreased their price target on shares of IQVIA from $290.00 to $260.00 and set a “buy” rating on the stock in a research note on Friday, November 1st. Finally, Redburn Atlantic began coverage on shares of IQVIA in a research note on Monday, October 14th. They issued a “buy” rating and a $276.00 price objective for the company. Four research analysts have rated the stock with a hold rating, seventeen have issued a buy rating and one has given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, IQVIA presently has an average rating of “Moderate Buy” and an average price target of $255.71.

IQVIA Stock Down 1.6 %

Shares of NYSE IQV opened at $203.59 on Wednesday. The firm’s 50-day moving average is $200.02 and its two-hundred day moving average is $221.09. The company has a market capitalization of $36.95 billion, a PE ratio of 26.72, a price-to-earnings-growth ratio of 2.14 and a beta of 1.48. The company has a debt-to-equity ratio of 1.76, a current ratio of 0.81 and a quick ratio of 0.81. IQVIA Holdings Inc. has a 12-month low of $187.62 and a 12-month high of $261.73.

About IQVIA

IQVIA Holdings Inc engages in the provision of advanced analytics, technology solutions, and clinical research services to the life sciences industry in the Americas, Europe, Africa, and the Asia-Pacific. It operates through three segments: Technology & Analytics Solutions, Research & Development Solutions, and Contract Sales & Medical Solutions.